| abstract |
According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), n n n wherein n R 1 represents C 1-6 alkyl or C 1-6 haloalkyl; n R 2 represents —C(═O)-aryl or —C(═O)-heteroaryl; n R 3 represents hydrogen, methyl (which may be in either the α or β configuration) or methylene; n R 4 and R 5 are the same or different and each represents hydrogen or halogen; and n represents a single or a double bond; n and salts and solvates thereof together with a long-acting β 2 -adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of COPD over a period of 24 hours or more. |